Exploring definitions of retention in care for people living with HIV in the United States in the modern treatment era.


Journal

AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219

Informations de publication

Date de publication:
01 07 2022
Historique:
entrez: 7 7 2022
pubmed: 8 7 2022
medline: 12 7 2022
Statut: ppublish

Résumé

To describe retention in HIV care based on various definitions of retention in the modern treatment era. A cohort study of people enrolled in care at seven mostly urban HIV clinics across the United States, 2010-2018. We estimated retention based on missed visits, kept visits, kept encounters (clinical visits, CD4 counts, and viral loads), and HIV labs. We contrasted risk factors for retention by different definitions and estimated odds ratios for of viral suppression and hazard ratios for mortality in 2 years immediately following the year in which retention was defined (the study year). Across 108 171 person-years (N = 21 481 people), in 71% of years people kept ≥75% of scheduled visits; in 78%, people kept ≥2 visits >90 days apart; in 74%, people had ≥2 HIV labs >90 days apart; and in 47%, people had no gaps >6 months in clinic visits. Missing >25% of scheduled visits despite attending ≥2 visits >90 days apart was associated with nonwhite non-Hispanic race/ethnicity, history of injection drug use, and prior AIDS diagnosis. In contrast, attending ≥75% of scheduled visits while not attending ≥2 visits >90 days apart was associated with male sex, white race, no injection drug use history, and no prior AIDS diagnosis. Subsequent viral nonsuppression was more strongly associated with missed- than kept-visit measures of retention; 2-year mortality was only associated with failure to be retained by missed-visit measures. Missed and kept-visit definitions of retention capture different constructs. Missed-visit measures are more strongly associated with poor HIV outcomes.

Identifiants

pubmed: 35796732
doi: 10.1097/QAD.0000000000003232
pii: 00002030-202207010-00014
pmc: PMC9273016
mid: NIHMS1797754
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1181-1189

Subventions

Organisme : NIAID NIH HHS
ID : P30 AI027767
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI094189
Pays : United States
Organisme : NIDA NIH HHS
ID : U01 DA036935
Pays : United States
Organisme : NIMH NIH HHS
ID : K08 MH118094
Pays : United States
Organisme : NIAID NIH HHS
ID : R24 AI067039
Pays : United States
Organisme : NIAAA NIH HHS
ID : K24 AA027483
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027763
Pays : United States
Organisme : NIAAA NIH HHS
ID : K01 AA028193
Pays : United States
Organisme : NIAID NIH HHS
ID : K01 AI131895
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI036219
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States

Informations de copyright

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Références

J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):129-32
pubmed: 24121761
J Air Waste Manag Assoc. 2003 Apr;53(4):442-50
pubmed: 12708508
PLoS One. 2014 Jul 10;9(7):e102305
pubmed: 25010739
J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):323-30
pubmed: 25140904
PLoS One. 2014 Nov 06;9(11):e111772
pubmed: 25375099
JAMA Intern Med. 2015 Apr;175(4):588-96
pubmed: 25706928
Clin Infect Dis. 2021 Dec 6;73(11):e3572-e3605
pubmed: 33225349
JAMA. 2020 Oct 27;324(16):1651-1669
pubmed: 33052386
Am J Epidemiol. 2008 Sep 15;168(6):656-64
pubmed: 18682488
J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):100-8
pubmed: 19295340
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
Sex Transm Dis. 2014 Jan;41(1):35-40
pubmed: 24326579
MMWR Morb Mortal Wkly Rep. 2018 Mar 22;68(11):267-272
pubmed: 30897075
Clin Infect Dis. 2022 Jan 29;74(2):171-179
pubmed: 33993219
Int J Epidemiol. 2016 Feb;45(1):140-50
pubmed: 26772869
AIDS. 2020 Aug 1;34(10):1519-1526
pubmed: 32675564
Epidemiology. 2020 Jul;31(4):570-577
pubmed: 32483067
J Acquir Immune Defic Syndr. 2017 Oct 01;76(2):141-148
pubmed: 28604501
JAMA. 2019 Mar 5;321(9):844-845
pubmed: 30730529
Epidemiology. 2003 Nov;14(6):680-6
pubmed: 14569183
AIDS Patient Care STDS. 2010 Oct;24(10):607-13
pubmed: 20858055
Clin Infect Dis. 2016 Apr 1;62(7):935-944
pubmed: 26679625
Clin Infect Dis. 2009 Jan 15;48(2):248-56
pubmed: 19072715
J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):574-80
pubmed: 23011397
Int J Epidemiol. 2008 Oct;37(5):948-55
pubmed: 18263650

Auteurs

Catherine R Lesko (CR)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Michael J Mugavero (MJ)

Division of Infectious Diseases, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.

Nicola M Shen (NM)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Anthony T Fojo (AT)

School of Medicine, Johns Hopkins University, Baltimore, Maryland.

Richard D Moore (RD)

School of Medicine, Johns Hopkins University, Baltimore, Maryland.

Jeanne C Keruly (JC)

School of Medicine, Johns Hopkins University, Baltimore, Maryland.

Edward R Cachay (ER)

Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, California.

Sonia Napravnik (S)

Division of Infectious Diseases, Department of Medicine.
Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina.

Kenneth H Mayer (KH)

The Fenway Institute, Fenway Health.
Department of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School.
Department of Global Health and Population, Harvard School of Public Health, Boston, Massachusetts.

Katerina A Christopoulos (KA)

Division of Infectious Diseases, HIV, and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California.

Jeffrey M Jacobson (JM)

School of Medicine, Case Western Reserve University, Cleveland, Ohio.

Peter F Rebeiro (PF)

Department of Medicine & Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

Geetanjali Chander (G)

School of Medicine, Johns Hopkins University, Baltimore, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH